Introducing Camena Bioscience, the groundbreaking startup founded by the visionary entrepreneur Steve Harvey and supported by renowned investors Mercia Asset Management PLC and ChromaCode, Inc. Raising over $10M in funding and located in the biotech hub of Saffron Walden, England, Camena is revolutionizing the field of biotechnology research with its mission to enable synthetic biologists with unprecedented precision and accuracy in gene access. By leveraging our cutting-edge technology, we provide genes for a diverse range of biotech customers in sectors such as pharmaceuticals, agriculture, and diagnostics.

Their unique approach grants access to long and complex gene sequences that were once challenging to produce. Serving companies worldwide, Camena is at the forefront of the synthetic biology revolution, empowering researchers to unlock the full potential of DNA synthesis. Their advanced nucleic acid synthesis technology enhances the quality and speed of synthesis, offering increased accuracy and unprecedented access to complex gene sequences. Join founder Steve Harvey, along with investors Mercia Asset Management PLC and ChromaCode, Inc., in shaping the future of biotechnology research with Camena Bioscience's groundbreaking solutions.